First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
Open accessAbstract
Educational Aims To illustrate the common mechanisms limiting exercise tolerance in patients with chronic lung and heart disease To highlight the impact of lung and heart disease on daily physical activity levels To outline the effects of cardiopulmonary rehabilitation on functional capacity in patients with chronic lung and heart disease To discuss an innovative tele-rehabilitation intervention using information and communications technologies to improve functional capacity in patients with chronic lung and heart disease Summary Shortness of breath associated with cardiorespiratory abnormalities and peripheral muscle discomfort are the major factors that limit exercise capacity in patients with chronic obstructive pulmonary disease (COPD) and those with congestive heart failure (CHF). Both of these symptoms negatively impact on patients’ daily physical activity levels. In turn, poor daily physical activity is commonly associated with increased rates of morbidity and mortality. Cardiopulmonary rehabilitation programmes partially reverse muscle weakness and dysfunction and increase functional capacity in both COPD and CHF. However, benefits gained from participation in cardiopulmonary rehabilitation programmes are regressing soon after the completion of these programmes. Moreover, several barriers limit access and uptake of cardiopulmonary rehabilitation programmes by eligible patients. A potential solution to the underutilisation of cardiopulmonary rehabilitation is the implementation of tele-rehabilitation interventions at home using information and communications technologies. Thus, tele-rehabilitation may be useful to encourage and educate patients with COPD or CHF on how best to maintain and/or further enhance daily physical activity levels.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Using radiolabeled SSTR antagonists, especially LM3 and JR11, may provide more successful imaging and PRRT strategies for neuroendocrine tumors, even those with relatively low SSTR expression, compared to agonists.
“Taking the proposed mechanism, preclinical and clinical studies into consideration, it is obvious that using radiolabeled SSTR antagonists, especially LM3 and JR11, may provide more successful imaging and PRRT strategies for neuroendocrine tumors, even those with relatively low SSTR expression (130, 137, 141) compared to agonists.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457 · see citing works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Öberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M. E., Fave, G. D., Kaltsas, G., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,746 · see citing works
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716 · see citing works
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 616 · see citing works
Öberg, K., Knigge, U., Kwekkeboom, D. J., & Perren, A. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 523 · see citing works
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 514 · see citing works
Aide, N., Lasnon, C., Veit-Haibach, P., Sera, T., Sattler, B., & Boellaard, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3740-2 · Cited by 344 · see citing works
Baum, R. P., & Kulkarni, H. (2012) · Theranostics · doi:10.7150/thno.3645 · Cited by 284 · see citing works
Somatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274 · see citing works
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267 · see citing works
Fani, M., Pozzo, L. D., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W., Reubi, J. C., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087999 · Cited by 262 · see citing works
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Hofland, J., Kaltsas, G., & de Herder, W. W. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz004 · Cited by 210 · see citing works
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Béhé, M. P., Brink, I., Rivier, J., Reubi, J. C., Maëcke, H. R., & Weber, W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 183 · see citing works
Nicolas, G. P., Schreiter, N. F., Kaul, F., Uiters, J., Bouterfa, H., Kaufmann, J., Erlanger, T. E., Cathomas, R. L., Christ, E., Fani, M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199760 · Cited by 174 · see citing works
Unexpected Sensitivity of sst<sub>2</sub> Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172 · see citing works
Nicolas, G. P., Mansi, R., McDougall, L., Kaufmann, J., Bouterfa, H., Wild, D., & Fani, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191684 · Cited by 148 · see citing works
van der Zwan, W. A., Brabander, T., Kam, B. L. R., Teunissen, J. J. M., Feelders, R. A., Hofland, J., Krenning, E. P., & de Herder, W. W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4158-1 · Cited by 146 · see citing works
Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24524 · Cited by 141 · see citing works
Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms
Baum, R. P., Kulkarni, H., & Carreras, C. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.01.002 · Cited by 134 · see citing works
Zhang, J., Kulkarni, H., Singh, A., Niepsch, K., Müller, D., & Baum, R. P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215848 · Cited by 122 · see citing works
Cescato, R., Érchegyi, J., Waser, B., Piccand, V., Maëcke, H. R., Rivier, J., & Reubi, J. C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701618q · Cited by 115 · see citing works
Reidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1026 · Cited by 112 · see citing works
Cescato, R., Waser, B., Fani, M., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095778 · Cited by 108 · see citing works
Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging
Baumann, T., Rottenburger, C., Nicolas, G., & Wild, D. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.01.003 · Cited by 105 · see citing works
Changes in the Epidemiology of Neuroendocrine Tumours
Huguet, I., Grossman, A. B., & O’Toole, D. (2015) · Neuroendocrinology · doi:10.1159/000441897 · Cited by 80 · see citing works
Werner, R. A., Weich, A., Kircher, M., Sólnes, L. B., Javadi, M. S., Higuchi, T., Buck, A. K., Pomper, M. G., Rowe, S. P., & Lapa, C. (2018) · Theranostics · doi:10.7150/thno.30357 · Cited by 78 · see citing works
Schuchardt, C., Kulkarni, H., Prasad, V., Zachert, C., Müller, D., & Baum, R. P. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_30 · Cited by 72 · see citing works
Aras, M., Erdıl, T. Y., Dane, F., Güngör, S., Jones, T., Dede, F., İnanır, S., & Turoğlu, H. T. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000401 · Cited by 57 · see citing works
From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
Zhang, J., Singh, A., Kulkarni, H., Schuchardt, C., Müller, D., Wester, H.-J., Μάινα, Θ., Rösch, F., van der Meulen, N. P., Müller, C., et al. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.002 · Cited by 52 · see citing works
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
Refardt, J. C., Hofland, J., Antwi, K., Nicolas, G. P., Rottenburger, C., Fani, M., Wild, D., & Christ, E. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09552-x · Cited by 50 · see citing works
Zhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41 · see citing works
Gupta, M., Choudhury, P. S., Rawal, S. K., Goel, H. C., & Rao, S. A. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-018-0548-3 · Cited by 38 · see citing works
Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
Bodei, L., & Weber, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.205161 · Cited by 30 · see citing works
Mansi, R., & Fani, M. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3755 · Cited by 29 · see citing works
An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts
Ramírez‐Rentería, C., Ferreira‐Hermosillo, A., Marrero–Rodríguez, D., Taniguchi‐Ponciano, K., Melgar, V., & Mercado, M. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.06.018 · Cited by 11 · see citing works
Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus
Bodei, L., Herrmann, K., Baum, R. P., Kidd, M. S., Malczewska, A., & Modlin, I. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219386 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481-1489.
- van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionu- clide therapy with [ 177 Lu-DOTA,Tyr 3 ]octreotate in patients with bronchial and gas- troenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46: 704-717.
Cited by
Sorted by citations
Borgna, F., Haller, S., Rodríguez, J. M. M., Ginj, M., Grundler, P. V., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05564-0 · Cited by 123 · see citing works
Yadav, M., Ballal, S., Sahoo, R., & Bal, C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05632-5 · Cited by 79 · see citing works
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
Lapi, S. E., Scott, P. J. H., Scott, A. M., Windhorst, A. D., Zeglis, B. M., Abdel–Wahab, M., Baum, R. P., Buatti, J. M., Giammarile, F., Kiess, A. P., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00030-5 · Cited by 89 · see citing works
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 86 · see citing works
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
Fortunati, E., Argalia, G., Zanoni, L., Fanti, S., & Ambrosini, V. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00967-z · Cited by 73 · see citing works
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Self-citationThe evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris, P. E., & Zhernosekov, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.941832 · Cited by 65 · see citing works
Carrier systems of radiopharmaceuticals and the application in cancer therapy
Zhang, T., Lei, H., Chen, X., Dou, Z., Yu, B., Su, W., Wang, W., Jin, X., Katsube, T., Wang, B., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01778-3 · Cited by 58 · see citing works
Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56 · see citing works
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57 · see citing works
Wild, D., Grønbæk, H., Navalkissoor, S., Haug, A. R., Nicolas, G. P., Pais, B., Ansquer, C., Beauregard, J., McEwan, A. J. B., Laßmann, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06383-1 · Cited by 54 · see citing works
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 50 · see citing works
Bidakhvidi, N. A., Goffin, K. E., Dekervel, J., Baete, K., Nackaerts, K., Clément, P. M., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2021) · Cancers · doi:10.3390/cancers14010129 · Cited by 48 · see citing works
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 46 · see citing works
Borgna, F., Barritt, P., Grundler, P. V., Talip, Z., Cohrs, S., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040536 · Cited by 45 · see citing works
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
Merola, E., & Grana, C. M. (2023) · Cancers · doi:10.3390/cancers15112975 · Cited by 44 · see citing works
di Santo, G., Santo, G., Sviridenko, A., & Virgolini, I. J. (2024) · Theranostics · doi:10.7150/thno.91268 · Cited by 42 · see citing works
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Ambrosini, V., Zanoni, L., Filice, A., Lamberti, G., Argalia, G., Fortunati, E., Campana, D., Versari, A., & Fanti, S. (2022) · Cancers · doi:10.3390/cancers14041055 · Cited by 42 · see citing works
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Salvia, A. L., Espinosa-Olarte, P., Martínez, M. C. R., Antón-Pascual, B., & García‐Carbonero, R. (2021) · Cancers · doi:10.3390/cancers13071701 · Cited by 33 · see citing works
Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics
Munekane, M., Fuchigami, T., & Ogawa, K. (2024) · Analytical Sciences · doi:10.1007/s44211-024-00514-w · Cited by 25 · see citing works
Hallqvist, A., Brynjarsdóttir, E., Krantz, T., Sjögren, M., Svensson, J., & Bernhardt, P. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268902 · Cited by 25 · see citing works
Molecular imaging Theranostics of Neuroendocrine Tumors
Fortunati, E., Bonazzi, N., Zanoni, L., Fanti, S., & Ambrosini, V. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.12.007 · Cited by 25 · see citing works
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Santo, G., di Santo, G., & Virgolini, I. J. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.02.002 · Cited by 23 · see citing works
Kersting, D., Sandach, P., Sraieb, M., Wiesweg, M., Metzenmacher, M., Darwiche, K., Oezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265664 · Cited by 17 · see citing works
Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms
Modica, R., Benevento, E., Liccardi, A., Cannavale, G., Minotta, R., Iasi, G. D., & Colao, A. A. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04140-4 · Cited by 22 · see citing works
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Karimi, A., Bogdani, C., O'Dwyer, E., & Siolas, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00938-1 · Cited by 19 · see citing works
The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?
Impériale, A., Jha, A., Meuter, L., Nicolas, G. P., Taïeb, D., & Pacák, K. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265406 · Cited by 19 · see citing works
Kuiper, J., Zoetelief, E., Brabander, T., de Herder, W. W., & Hofland, J. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13469 · Cited by 18 · see citing works
Beykan, S., Eberlein, U., Ansquer, C., Beauregard, J., Durand‐Gasselin, L., Grønbæk, H., Haug, A. R., Hicks, R. J., Lenzo, N. P., Navalkissoor, S., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06682-1 · Cited by 18 · see citing works
Iravani, A., Parihar, A. S., Akhurst, T., & Hicks, R. J. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00465-3 · Cited by 16 · see citing works
Richter, S., Steenblock, C., Fischer, A., Lemm, S., Ziegler, C. G., Bechmann, N., Nölting, S., Pietzsch, J., & Ullrich, M. (2023) · Theranostics · doi:10.7150/thno.87345 · Cited by 16 · see citing works
Perrone, E., Ghai, K., Eismant, A., Andreassen, M., Langer, S. W., Knigge, U., Kjær, A., & Baum, R. P. (2024) · Diagnostics · doi:10.3390/diagnostics14090907 · Cited by 16 · see citing works
Kanellopoulos, P., Nock, B. A., Greifenstein, L., Baum, R. P., Roesch, F., & Μάινα, Θ. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314590 · Cited by 15 · see citing works
Clinical Pharmacology of Radiotheranostics in Oncology
Beek, E. T. T., Burggraaf, J., Teunissen, J. J. M., & Vriens, D. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2598 · Cited by 15 · see citing works
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy
Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., & Li, J. (2025) · Biomimetics · doi:10.3390/biomimetics10060394 · Cited by 15 · see citing works
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
Echavidre, W., Fagret, D., Faraggi, M., Picco, V., & Montemagno, C. (2023) · Cancers · doi:10.3390/cancers15194839 · Cited by 14 · see citing works
Guo, W., Wen, X., Chen, Y., Zhao, T., Liu, J., Tao, Y., Fu, H., Wang, H., Xu, W., Pang, Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.022 · Cited by 14 · see citing works
Liu, M., Ren, C., Zhang, H., Zhang, Y., Huang, Z., Jia, R., Cheng, Y., Bai, C., Xu, Q., Zhu, W., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06790-y · Cited by 14 · see citing works
Boursier, C., Zaragori, T., Imbert, L., & Verger, A. (2024) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.24.03571-4 · Cited by 14 · see citing works
Papadakis, G. Z., Karantanas, A. H., Kostas Marias, A., & Millo, C. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109932 · Cited by 14 · see citing works
Viswanathan, R., Ballal, S., Yadav, M. P., Roesch, F., Sheokand, P., Satapathy, S., Tripathi, M., Agarwal, S., Moon, E. S., & Bal, C. (2024) · Pharmaceuticals · doi:10.3390/ph17030275 · Cited by 13 · see citing works
Radiometal-theranostics: the first 20 years*
Roesch, F., & Martin, M. (2022) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-022-08624-3 · Cited by 13 · see citing works
Grey, N., Silosky, M. S., Lieu, C. H., & Chin, B. B. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i17.1768 · Cited by 11 · see citing works
Nguyen, N. T., Min, Y., Rivière, J., van der Garde, M., Ghosh, S. C., Bartos, L. M., Brendel, M., Bassermann, F. C., Azhdarinia, A., Weber, W., et al. (2025) · Theranostics · doi:10.7150/thno.113354 · Cited by 11 · see citing works
Nock, B. A., Kanellopoulos, P., Moon, E. S., Rouchota, M. G., Loudos, G. K., Ballal, S., Yadav, M. P., Bal, C. S., Mishra, P. K., Sheokand, P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030776 · Cited by 11 · see citing works
Novel bio-carriers for radionuclide delivery in cancer radiotherapy
Wang, L., He, Q., Man, J., Gao, Y., Zhou, G., Si, H., Yang, K., Hu, L. T., & Pei, P. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216557 · Cited by 10 · see citing works
Perrone, E., Calcagni, M. L., Leccisotti, L., Moretti, R., Ghai, K., Eismant, A., Parkar, T., Greifenstein, L., & Baum, R. P. (2025) · Cancers · doi:10.3390/cancers17183070 · Cited by 8 · see citing works
Virgolini, I. J., di Santo, G., & Santo, G. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07750-w · Cited by 8 · see citing works
Bodei, L., Gnanasegaran, G., Giammarile, F., Pavel, M., Ambrosini, V., Baum, R. P., Hörsch, D., Howe, J. R., Cremonesi, M., El-Haddad, G., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100017 · Cited by 8 · see citing works
New horizon of radiopharmaceuticals in management of neuroendocrine tumors
Haq, A., Rayamajhi, S. J., Ponisio, M. R., & Prasad, V. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101797 · Cited by 8 · see citing works
Shanmugiah, J., & Kim, J. S. (2026) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-026-00988-8 · Cited by 7 · see citing works
Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside
Mansi, R., & Fani, M. (2021) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2021.500 · Cited by 7 · see citing works
Yamaguchi, N., Wei, J., & Isomoto, H. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02241-z · Cited by 6 · see citing works
Recent Trends in Radiopharmaceuticals: Focused on Drug Delivery to the Targeted Tissues
Ito, T., Hachisuka, A., Ishii‐Watabe, A., Saito, Y., Demizu, Y., & Misawa, T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00407 · Cited by 5 · see citing works
Wang, Q., Librizzi, D., Bagheri, S., Ebrahimifard, A., Shamami, A. H., Rinke, A., Eilsberger, F., Luster, M., & Yousefi, B. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178539 · Cited by 5 · see citing works
Cai, J., Zhu, Y., Zhu, X., Hosmane, N. S., Ding, Q., & Zhu, Y. Z. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217448 · Cited by 5 · see citing works
Fricke, J. G., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Schmid, D. E., Borgna, F., Fani, M., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270654 · Cited by 5 · see citing works
Speicher, T., Burgard, C., Bastian, M. B., Rosar, F., Bartholomä, M. D., Maus, S., & Ezziddin, S. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005439 · Cited by 5 · see citing works
Hindié, E., Baudin, É., Hicks, R. J., & Taïeb, D. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264422 · Cited by 5 · see citing works
New approaches in nuclear medicine theranostics
Enke, J. S., Fenzl, L., Lapa, C., & Viering, O. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf143 · Cited by 4 · see citing works
Smith, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1572118 · Cited by 4 · see citing works
Baberwal, P., & Basu, S. K. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2589524 · Cited by 4 · see citing works
Resch, S., & Delker, A. (2026) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2026.03.011 · Cited by 4 · see citing works
Ordas, L., Foster, S., Pham, P., Ollendorff, A. S., Gnanasekar, V., Toulany, M., & Sodji, Q. H. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkag056 · Cited by 4 · see citing works
Shekhda, K. M., & Navalkissoor, S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.07.002 · Cited by 4 · see citing works
Radiopharmaceuticals in Nasopharyngeal Cancer
Xu, X., Tang, X., Wu, W.-Y., Liu, M., & Zeng, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108281 · Cited by 4 · see citing works
Molecular Imaging in neuroendocrine neoplasias
Christ, E., Wild, D., & Refardt, J. C. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104115 · Cited by 4 · see citing works
Preliminary experiments to produce lutetium-177 in the TRR-1/M1 Thai research reactor
Ragchana, P., Saengkaew, P., Wetchagarun, S., Tiyapun, K., Dangprasert, M., & Khamwan, K. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.111708 · Cited by 3 · see citing works
Liu, M., Zhang, Y., Yan, X., Zhang, H., Ren, C., Huang, Z., Cheng, Y., Xu, Q., Li, Y., Jia, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07484-9 · Cited by 3 · see citing works
Deroose, C. M., Ambrosini, V., Hofland, J., Kaltsas, G., Kjær, A., Lamarca, Á., Sowa-Staszczak, A., Janson, E. T., & Fazio, N. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70220 · Cited by 3 · see citing works
Small Bowel Neuroendocrine Neoplasms—A Review
Vulasala, S. S., Virarkar, M., Gopireddy, D. R., Waters, R., Alkhasawneh, A., Awad, Z. T., Maxwell, J. E., Ramani, N. S., Kumar, S. P., Onteddu, N. K. R., et al. (2023) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001541 · Cited by 3 · see citing works
Xing, H., Zhu, W., Cheng, Y., Yang, Q., Jia, R., Zhao, H., Bai, C., Huo, L., & Wu, W. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000101 · Cited by 3 · see citing works
Zhu, W., Liu, M., & Huo, L. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000122 · Cited by 2 · see citing works
Theranostic Imaging and Radiopharmaceutical Therapy
Duan, H., & Iagaru, A. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_22 · Cited by 2 · see citing works
Mansi, R., Bertarelli, N., Pozzo, L. D., Zanger, S., Bernabeu, T. B., Maëcke, H. R., & Fani, M. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00363-6 · Cited by 2 · see citing works
Greifenstein, L., Martin, M., Stephan, S., Eismant, A., Kramer, C. S., Landvogt, C., Mueller, C., Rösch, F., & Baum, R. P. (2026) · Pharmaceuticals · doi:10.3390/ph19010172 · Cited by 2 · see citing works
Practical Aspects of 161Tb Production
Skálová, M., Janská, T., Štíbr, M., Vlk, M., Šoltés, J., Vins, M., Hassfjell, S. P., Muller, J., & Kozempel, J. (2026) · Pharmaceuticals · doi:10.3390/ph19040619 · Cited by 2 · see citing works
Baum, R. P., Zhao, T., Jakobsson, V., Greifenstein, L., Eismant, A., Ghai, K., Mishra, A., Klega, A., Landvogt, C., Mueller, C., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271129 · Cited by 2 · see citing works
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies
Grewal, U. S., Shaheen, S., Zhen, D. B., Mittra, E., Halfdanarson, T. R., Singh, S., & Chan, J. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-518934 · Cited by 2 · see citing works
State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms
Ambrosini, V., Fortunati, E., Fanti, S., Ursprung, S., Asmundo, L., O’Shea, A., Kako, B., Lee, S. I., Furtado, F., Blake, M. A., et al. (2024) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001594 · Cited by 2 · see citing works
Wild, D., & Fani, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_16 · Cited by 1 · see citing works
Speicher, T., Burgard, C., Rosar, F., Bastian, M. B., Bartholomä, M. D., Maus, S., & Ezziddin, S. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005938 · Cited by 1 · see citing works
Radionuclides for imaging and therapy in oncology
Velikyan, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00026-1 · Cited by 1 · see citing works
Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives
Ai, D., Li, J., Shi, J., Sang, S., Zhang, B., Ge, S., & Deng, S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114865 · Cited by 1 · see citing works
Bogdani, C., Karimi, A., Li, R., Atkinson, E. C., Oberstein, P. E., & Siolas, D. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00833 · Cited by 1 · see citing works
Clinical Applications of Theranostics
Kuten, J., Bodei, L., & Lewis, J. S. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_17 · Cited by 1 · see citing works
Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation
Liu, J., Zuo, X., Yang, X., Wang, X., Gan, L., & Xue, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02695-6 · Cited by 1 · see citing works
Update on PET Imaging of Neuroendocrine Neoplasms
Singh, C., Gupta, M., Panda, A., Prakash, A., Mhlanga, J. C., Catalano, O. A., & Virarkar, M. (2026) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2026.06.006 · Cited by 1 · see citing works
Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions
Nazar, A. K., & Basu, S. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006120 · Cited by 1 · see citing works
So, E., Morizane, C., & Okusaka, T. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261471127 · Cited by 1 · see citing works
Bakr, H., Al-Awar, A., Spetz, J. K. E., & Forssell-Aronsson, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198709 · Cited by 1 · see citing works
May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine
Ekmekçioğlu, Ö., Hughes, S., Fendler, W. P., Verzijlbergen, F. J., Kong, G., & Hofman, M. S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06877-6 · Cited by 1 · see citing works
Ballal, S., Sheokand, P., Yadav, M. P., Roesch, F., Viswanathan, R., Satapathy, S., Tripathi, M., Moon, E. S., Mishra, P., Rastogi, S., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005649 · Cited by 1 · see citing works
Perrone, E., Ghai, K., Eismant, A., & Baum, R. P. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005782 · Cited by 1 · see citing works
Peptidradiorezeptor-Therapie (PRRT)
Buck, A. K., Lapa, C., Weich, A., Higuchi, T., Hasenauer, N., Hänscheid, H., & Werner, R. A. (2021) · Der Nuklearmediziner · doi:10.1055/a-1556-8323
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Theranostics in Neuroendocrine Tumors
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_21
Greifenstein, L., Kramer, C. S., Grus, T., Rösch, F., Klega, A., Landvogt, C., Müller, C., Marx, S., & Baum, R. P. (2023) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0043-1766141
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy
Stasio, G. D. D., Farulla, L. S. A., Botta, F., Gilardi, L., & Grana, C. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_14
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., Iasi, G. D., & Colao, A. A. L. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_265
- Authors
- Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H.
- Affiliations
- Zentralklinik Bad Berka (DE)
- National University of Singapore (SG)
- University Medical Center Freiburg (DE)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2021-03-05
- Volume
- 62
- Issue
- 11
- Pages
- 1571-1581
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC8612334
- OpenAlex
- W3133553083
- Cited by
- 127
- References
- 38
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 18 · 2023: 19 · 2022: 15 · 2021: 8
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- somatostatin receptor antagonists, peptide receptor radionuclide therapy, metastatic neuroendocrine tumors, dosimetry, treatment safety, treatment efficacy
- MeSH terms
- Adult, Aged, Female, Humans, Lutetium, Male, Middle Aged, Neoplasm Metastasis, Organometallic Compounds, Radioisotopes, Radiometry, Safety, Octreotide, Treatment Outcome, Receptors, Somatostatin, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
